Quick Answer
Stoke Therapeutics, Inc. reported Earnings Per Share Diluted of $0.12 (loss) per share for the year ending 2025.
- Stoke Therapeutics, Inc. showed an increase of +92.7% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Stoke Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $0.60 (loss) per share | Q3 2021: $0.60 (loss) per share | Q1 2022: $0.66 (loss) per share | Q2 2022: $0.63 (loss) per share | Q3 2022: $0.66 (loss) per share | Q1 2023: $0.53 (loss) per share | Q2 2023: $0.69 (loss) per share | Q3 2023: $0.55 (loss) per share | Q1 2024: $0.57 (loss) per share | Q2 2024: $0.46 (loss) per share | Q3 2024: $0.47 (loss) per share | Q1 2025: $1.90 per share | Q2 2025: $0.40 (loss) per share | Q3 2025: $0.65 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), Stoke Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 94.9%.
- Historical annual values: Fiscal year 2025: $0.12 (loss) per share | Fiscal year 2024: $1.65 (loss) per share | Fiscal year 2023: $2.38 (loss) per share | Fiscal year 2022: $2.60 (loss) per share | Fiscal year 2021: $2.34 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: